Skip Ribbon Commands
Skip to main content
Dr Chen Yun Xin from SGH

Dr Chen Yunxin



Specialty: Haematology, Haematology

Sub-specialties: Lymphoma, Myeloma

Conditions Treated by this Doctor:
Acute Lymphocytic Leukemia (ALL), Deep Vein Thrombosis, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Pulmonary Embolism, Thalassaemia.

Clinical Appointments

  • Consultant SingHealth Duke-NUS Blood Cancer Centre
  • Consultant SingHealth Duke-NUS Transplant Centre
  • Consultant Haematology Singapore General HospitalSingapore General Hospital


​Dr Chen received her MBBS from the Yong Loo Lin School of Medicine in 2008 and attained MRCP in 2011.  She then completed specialist training in Haematology at Singapore General Hospital in 2015 and received the FRCPath qualification in 2016. Her primary interest is in multiple myeloma.


  • ​FRCPath (UK): 2016
  • MRCP (UK): 2011
  • MBBS (Singapore): 2008

Professional Appointments and Committee Memberships

  • Adjunct Instructor, DUKE-NUS Medical School
  • Clinical Lecturer, NUS YLL School of Medicine
  • Member, Singapore Multiple Myeloma Study Group
  • Member, Singapore Society of Haematology


  • SingHealth Quality Service Award – Gold (2017)
  • MOH Healthcare Research Scholarship (2016)
  • SingHealth Quality Service Award – Silver (2015)
  • SGH Moments Award (2013)
  • SingHealth Quality Improvement Project - Best Team (Safely Receive, Soundly Sleep) (2013)

Research Interests


Thrombotic microangiopathy during carfilzomib use: case series in Singapore.
Chen Y, Ooi M, Lim SF, Lin A, Lee J, Nagarajan C, et al.
Blood Cancer J. 2016;6(7):e450.

Concurrent β-thalassaemia trait and Southeast Asian ovalocytosis associated with clinically significant iron loading. 
Chen Y, Law HY, Tan GP, Ang AL. 
Blood Cells Mol Dis. 2016;63:25-6.

Occult recurrence of monomorphic epitheliotropic intestinal T-cell lymphoma and the role of MATK gene expression in diagnosis
Chen Y, Tan SY, Petersson BF, Khor YM, Gopalakrishnan SK, Tan D.
Hematol Oncol. 2016 Mar. doi: 10.1002/hon.2288.

The Singapore Myeloma Study Group Consensus Guidelines for the management of patients with multiple myeloma.
de Mel S, Chen Y, Gopalakrishnan SK, Ooi M, Teo C, Tan D, et al. 
Singapore Med J. 2017;58(2):55-71.

Early relapse post autologous transplant is a stronger predictor of survival compared to pretreatment patient factors in the novel agent era – analysis of Singapore multiple myeloma working group
Ong SY, Widanalage SM, Chen Y, Ooi MG, Surendran S, Lin A, Koh LP, Linn YC, Ho AYL, Hwang WYK, Phipps C, Loh SMY, Goh YT, Tan D, Chng WJ, Gopalakrishnan SK.
Bone Marrow Transplant. 2016;51(7):933-7.

Lymphoproliferative Disease and Hepatitis B Reactivation: Challenges in the Era of Rapidly Evolving Targeted Therapy.
Phipps C, Chen Y, Tan D.
Clin Lymphoma Myeloma Leuk. 2016;16(1):5-11.

Daratumumab and its potential in the treatment of multiple myeloma: overview of the preclinical and clinical development.
Phipps C, Chen Y, Gopalakrishnan S, Tan D.
Ther Adv Hematol. 2015;6(3):120-7.

Subcutaneous bortezomib combined with weekly cyclophosphamide and dexamethasone is an efficient and well tolerated regime in newly diagnosed multiple myeloma.
Ong SY, Ng HY, Surendran S, Linn YC, Chen Y, Goh YT, Diong C, Gopalakrishnan SK.
Br J Haematol. 2015;169(5):754-6.

Research Trials